March 29, 2017 11:43 PM ET

Biotechnology

Company Overview of Maxim Pharmaceuticals Inc.

Company Overview

Maxim Pharmaceuticals, Inc., a biopharmaceutical company, develops cancer therapeutics. Its lead drug candidate, Ceplene, is in a phase III clinical trial as a remission maintenance therapy for patients with acute myeloid leukemia, a form of adult leukemia. The company’s Apoptosis drug is under preclinical trial; and MX8899, which is in phase I and II clinical trials for oral mucositis and radiation dermatitis. Maxim also has Ceplene for chronic liver disease under phase I and phase II clinical trials. Ceplene prevents or reverses damage associated with oxidative stress, thereby protecting critical cells and tissues. The company also engages in the discovery and development of small-molecule...

8899 University Center Lane

Suite 400

San Diego, CA 92122

United States

Founded in 1954

32 Employees

Phone:

858-453-4040

Fax:

858-453-5005

Key Executives for Maxim Pharmaceuticals Inc.

Maxim Pharmaceuticals Inc. does not have any Key Executives recorded.

Maxim Pharmaceuticals Inc. Key Developments

Maxim Pharmaceuticals Inc. Announces Board Appointments

Immune Pharmaceuticals Inc. announced that it has entered into a consulting agreement with Joseph V. Pergolizzi Jr., MD. Dr. Pergolizzi will form an operational management team, a Scientific Advisory Board, and a Board of Directors for Maxim Pharmaceuticals Inc., in order to advance the development of Amiket. Pergolizzi is the co-founder and Chief Operating Officer of NEMA Research and president of Naples Anesthesia and Pain Associates of Naples, Florida. He has also held Chief Medical Officer positions at several pharmaceutical companies.

Immune Pharmaceuticals Designates Maxim Pharmaceuticals as its Pain and Neurology Subsidiary

Immune Pharmaceuticals has announced that the Board of Directors has approved to designate Maxim Pharmaceuticals as the dedicated entity to develop and commercialize, and hold the intellectual property related to, AmiKet and other related pain and neurology assets.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 15, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Maxim Pharmaceuticals Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.